Skip to main content
SpringerLink
Log in

Post-operative Management

  • Chapter
  • First Online:
Corneal Transplantation

  • 838 Accesses

Abstract

Corneal transplantation has been successfully performed for over 100 years. Despite HLA typing and systemic immunosuppression not being routinely undertaken, 5-year survival rates exceed 90 % in corneal grafts with no current or past history of inflammation. However, graft survival decreases dramatically in the presence of risk factors that place it at high rejection risk, and immunological graft rejection remains the leading cause for graft failure. Post-operative management of corneal grafts requires stratification according to the risk for rejection and addressing this with appropriate prophylaxis. It is critically important to recognise corneal graft rejection early and initiate appropriate treatment, as a delay in diagnosis and treatment will result in failure to reverse rejection, or at least shorter graft survival if rejection is reversed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Niederkorn JY, Larkin DF. Immune privilege of corneal allografts. Ocul Immunol Inflamm. 2010;18(3):162–71.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Coster D, Jessup CF, Williams K. Mechanisms of corneal allograft rejection and the development of new therapies. In: Reinhard T, Larkin DF, editors. Corneal allotransplantation, allergic disease and trachoma. Berlin: Springer; 2010. p. 163.

    Google Scholar 

  3. Bill A. The blood-aqueous barrier. Trans Ophthalmol Soc U K. 1986;105(Pt 2):149–55.

    PubMed  Google Scholar 

  4. Niederkorn JY. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol. 2002;22(1):13–46.

    Article  CAS  PubMed  Google Scholar 

  5. Streilein JW, Niederkorn JY. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med. 1981;153(5):1058–67.

    Article  CAS  PubMed  Google Scholar 

  6. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270(5239):1189–92.

    Article  CAS  PubMed  Google Scholar 

  7. Hori J, Wang M, Miyashita M, Tanemoto K, Takahashi H, Takemori T, et al. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J Immunol. 2006;177(9):5928–35.

    Article  CAS  PubMed  Google Scholar 

  8. Shen L, Jin Y, Freeman GJ, Sharpe AH, Dana MR. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival. J Immunol. 2007;179(6):3672–9.

    Article  CAS  PubMed  Google Scholar 

  9. Goslings WR, Prodeus AP, Streilein JW, Carroll MC, Jager MJ, Taylor AW. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest Ophthalmol Vis Sci. 1998;39(6):989–95.

    CAS  PubMed  Google Scholar 

  10. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci. 1993;34(13):3579–84.

    CAS  PubMed  Google Scholar 

  11. Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci. 1984;25(5):519–24.

    CAS  PubMed  Google Scholar 

  12. Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci. 1997;38(6):1277–82.

    CAS  PubMed  Google Scholar 

  13. Apte RS, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol. 1996;156(8):2667–73.

    CAS  PubMed  Google Scholar 

  14. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niederkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160(12):5693–6.

    CAS  PubMed  Google Scholar 

  15. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, et al. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol. 1986;136(10):3916–20.

    CAS  PubMed  Google Scholar 

  16. Williams KA, Lowe MT, Keane MC, Jones VJ, Loh RS, Coster DJ. The Australian corneal graft registry 2012 report. Adelaide: Snap Printing; 2012.

    Google Scholar 

  17. Arentsen JJ. Corneal transplant allograft reaction: possible predisposing factors. Trans Am Ophthalmol Soc. 1983;81:361–402.

    PubMed Central  CAS  PubMed  Google Scholar 

  18. Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994;101(9):1536–47.

    Article  CAS  PubMed  Google Scholar 

  19. Volker-Dieben HJ, D’Amaro J, Kok-van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol. 1987;15(1):11–8.

    Article  CAS  PubMed  Google Scholar 

  20. Williams KA, White MA, Ash JK, Coster DJ. Leukocytes in the graft bed associated with corneal graft failure. Analysis by immunohistology and actuarial graft survival. Ophthalmology. 1989;96(1):38–44.

    Article  CAS  PubMed  Google Scholar 

  21. Williams KA, Esterman AJ, Bartlett C, Holland H, Hornsby NB, Coster DJ. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation. 2006;81(6):896–901.

    Article  PubMed  Google Scholar 

  22. Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol. 2005;140(6):1112–22.

    Article  PubMed  Google Scholar 

  23. Thompson Jr RW, Price MO, Bowers PJ, Price Jr FW. Long-term graft survival after penetrating keratoplasty. Ophthalmology. 2003;110(7):1396–402.

    Article  PubMed  Google Scholar 

  24. Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G, et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol. 2010;184(2):535–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Boisjoly HM, Tourigny R, Bazin R, Laughrea PA, Dube I, Chamberland G, et al. Risk factors of corneal graft failure. Ophthalmology. 1993;100(11):1728–35.

    Article  CAS  PubMed  Google Scholar 

  26. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology. 1992;99(3):403–14.

    Article  CAS  PubMed  Google Scholar 

  27. Reinhard T, Moller M, Sundmacher R. Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A. Cornea. 1999;18(6):645–51.

    Article  CAS  PubMed  Google Scholar 

  28. Beauregard C, Stevens C, Mayhew E, Niederkorn JY. Cutting edge: atopy promotes Th2 responses to alloantigens and increases the incidence and tempo of corneal allograft rejection. J Immunol. 2005;174(11):6577–81.

    Article  CAS  PubMed  Google Scholar 

  29. Kuchle M, Cursiefen C, Nguyen NX, Langenbucher A, Seitz B, Wenkel H, et al. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):580–4.

    Article  PubMed  Google Scholar 

  30. Nguyen NX, Martus P, Seitz B, Cursiefen C. Atopic dermatitis as a risk factor for graft rejection following normal-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2009;247(4):573–4.

    Article  PubMed  Google Scholar 

  31. Niederkorn JY, Chen PW, Mellon J, Stevens C, Mayhew E. Allergic airway hyperreactivity increases the risk for corneal allograft rejection. Am J Transplant. 2009;9(5):1017–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Flynn TH, Ohbayashi M, Ikeda Y, Ono SJ, Larkin DF. Effect of allergic conjunctival inflammation on the allogeneic response to donor cornea. Invest Ophthalmol Vis Sci. 2007;48(9):4044–9.

    Article  PubMed  Google Scholar 

  33. Jonas JB, Rank RM, Budde WM. Immunologic graft reactions after allogenic penetrating keratoplasty. Am J Ophthalmol. 2002;133(4):437–43.

    Article  PubMed  Google Scholar 

  34. Paufique L, Sourdille GD, Offret G. Les Greffes de la Cornee. 27. Paris: Masson et Cie; 1948. p. 131–6.

    Google Scholar 

  35. Khodadoust AA, Silverstein AM. Transplantation and rejection of individual cell layers of the cornea. Invest Ophthalmol. 1969;8(2):180–95.

    CAS  PubMed  Google Scholar 

  36. Chan CM, Wong TY, Yeong SM, Lim TH, Tan DT. Penetrating keratoplasty in the Singapore National Eye Centre and donor cornea acquisition in the Singapore Eye Bank. Ann Acad Med Singapore. 1997;26(4):395–400.

    CAS  PubMed  Google Scholar 

  37. Adler H, Beland JL, Kozlow W, Del-Pan NC, Kobzik L, Rimm IJ. A role for transforming growth factor-beta1 in the increased pneumonitis in murine allogeneic bone marrow transplant recipients with graft-versus-host disease after pulmonary herpes simplex virus type 1 infection. Blood. 1998;92(7):2581–9.

    CAS  PubMed  Google Scholar 

  38. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981;99(4):599–604.

    Article  CAS  PubMed  Google Scholar 

  39. Krachmer JH, Alldredge OC. Subepithelial infiltrates: a probable sign of corneal transplant rejection. Arch Ophthalmol. 1978;96(12):2234–7.

    Article  CAS  PubMed  Google Scholar 

  40. Slegers TPAM, Daly MK, Larkin DF. Corneal transplant rejection. In: Reinhard T, Larkin DF, editors. Essentials in ophthalmology: cornea and external eye disease. New York: Springer; 2006.

    Google Scholar 

  41. Larkin DF. Corneal allograft rejection. Br J Ophthalmol. 1994;78(8):649–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Claerhout I, Beele H, De Bacquer D, Kestelyn P. Factors influencing the decline in endothelial cell density after corneal allograft rejection. Invest Ophthalmol Vis Sci. 2003;44(11):4747–52.

    Article  PubMed  Google Scholar 

  43. Naacke HG, Borderie VM, Bourcier T, Touzeau O, Moldovan M, Laroche L. Outcome of corneal transplantation rejection. Cornea. 2001;20(4):350–3.

    Article  CAS  PubMed  Google Scholar 

  44. McDonnell PJ, Enger C, Stark WJ, Stulting RD. Corneal thickness changes after high-risk penetrating keratoplasty. Collaborative Corneal Transplantation Study Group. Arch Ophthalmol. 1993;111(10):1374–81.

    Article  CAS  PubMed  Google Scholar 

  45. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology. 1991;98(3):329–33.

    Article  CAS  PubMed  Google Scholar 

  46. Hill JC, Ivey A. Corticosteroids in corneal graft rejection: double versus single pulse therapy. Cornea. 1994;13(5):383–8.

    Article  CAS  PubMed  Google Scholar 

  47. Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83(12):1348–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Costa DC, de Castro RS, Kara-Jose N. Case–control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection. Eye (Lond). 2009;23(3):708–14.

    Article  CAS  Google Scholar 

  49. Poon A, Constantinou M, Lamoureux E, Taylor HR. Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol. 2008;36(5):415–21.

    PubMed  Google Scholar 

  50. Zhao JC, Jin XY. Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol. 1995;119(2):189–94.

    Article  CAS  PubMed  Google Scholar 

  51. Young AL, Rao SK, Cheng LL, Wong AK, Leung AT, Lam DS. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Eye (Lond). 2002;16(3):304–8.

    Article  CAS  Google Scholar 

  52. Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of corneal graft rejection in the United kingdom. Cornea. 2005;24(3):292–6.

    Article  PubMed  Google Scholar 

  53. Rinne JR, Stulting RD. Current practices in the prevention and treatment of corneal graft rejection. Cornea. 1992;11(4):326–8.

    Article  CAS  PubMed  Google Scholar 

  54. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea. 2006;25(3):286–90.

    Article  PubMed  Google Scholar 

  55. Price Jr FW, Price DA, Ngakeng V, Price MO. Survey of steroid usage patterns during and after low-risk penetrating keratoplasty. Cornea. 2009;28(8):865–70.

    Article  PubMed  Google Scholar 

  56. Nguyen NX, Seitz B, Martus P, Langenbucher A, Cursiefen C. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol. 2007;144(2):318–9.

    Article  CAS  PubMed  Google Scholar 

  57. Price MO, Price Jr FW. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology. 2006;113(10):1785–90.

    Article  PubMed  Google Scholar 

  58. Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Woodward JG. Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune-privileged site. J Immunol. 1996;157(6):2262–71.

    CAS  PubMed  Google Scholar 

  59. Okada K, Mishima HK, Kawano MM, Mizote H, Minamoto A. Involvement of CD8+ RT1.B+ and CD4+ RT1.B+ cells of cervical lymph nodes in the immune response after corneal transplantation in the rat. Jpn J Ophthalmol. 1997;41(4):209–16.

    Article  CAS  PubMed  Google Scholar 

  60. Yamagami S, Dana MR. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 2001;42(6):1293–8.

    CAS  PubMed  Google Scholar 

  61. Chatel MA, Larkin DF. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol. 2010;150(2):179–84.

    Article  CAS  PubMed  Google Scholar 

  62. Flynn TH, Mitchison NA, Ono SJ, Larkin DF. Aqueous humor alloreactive cell phenotypes, cytokines and chemokines in corneal allograft rejection. Am J Transplant. 2008;8(7):1537–43.

    Article  CAS  PubMed  Google Scholar 

  63. Hill JC. Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye (Lond). 1995;9(Pt 4):422–8.

    Google Scholar 

  64. Reinhard T, Reis A, Bohringer D, Malinowski M, Voiculescu A, Heering P, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years’ results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol. 2001;239(5):367–72.

    Article  CAS  PubMed  Google Scholar 

  65. Poon AC, Forbes JE, Dart JK, Subramaniam S, Bunce C, Madison P, et al. Systemic cyclosporin A in high risk penetrating keratoplasties: a case–control study. Br J Ophthalmol. 2001;85(12):1464–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U. Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol. 2002;86(9):988–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  67. Reinhard T, Mayweg S, Sokolovska Y, Seitz B, Mittelviefhaus H, Engelmann K, et al. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transplant Int. 2005;18(6):703–8.

    Article  CAS  Google Scholar 

  68. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology. 1994;101(1):128–33.

    Article  CAS  PubMed  Google Scholar 

  69. Sinha R, Jhanji V, Verma K, Sharma N, Biswas NR, Vajpayee RB. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 2010;248(8):1167–72.

    Article  CAS  PubMed  Google Scholar 

  70. Inoue K, Amano S, Kimura C, Sato T, Fujita N, Kagaya F, et al. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol. 2000;44(3):302–5.

    Article  CAS  PubMed  Google Scholar 

  71. Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ. Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens. 2003;29(2):103–7.

    Article  PubMed  Google Scholar 

  72. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology. 1989;96(8):1144–50.

    Article  CAS  PubMed  Google Scholar 

  73. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ. 1999;318(7191):1104–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  74. Mills RA, Jones DB, Winkler CR, Wallace GW, Wilhelmus KR. Topical FK-506 prevents experimental corneal allograft rejection. Cornea. 1995;14(2):157–60.

    Article  CAS  PubMed  Google Scholar 

  75. Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea. 2008;27(4):488–93.

    Article  PubMed  Google Scholar 

  76. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 2001;108(10):1838–44.

    Article  CAS  PubMed  Google Scholar 

  77. Joseph A, Raj D, Shanmuganathan V, Powell RJ, Dua HS. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol. 2007;91(1):51–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  78. Yamazoe K, Yamaguchi T, Omoto M, Shimazaki J. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine. Cornea. 2014;33(11):1157–63.

    Article  PubMed  Google Scholar 

  79. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66(4):507–15.

    Article  CAS  PubMed  Google Scholar 

  80. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997;63(1):39–47.

    Article  CAS  PubMed  Google Scholar 

  81. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation. 1999;68(3):391–6.

    Google Scholar 

  82. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996;61(7):1029–37.

    Google Scholar 

  83. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transplant. 2001;7(5):442–50.

    Article  CAS  Google Scholar 

  84. Birnbaum F, Mayweg S, Reis A, Bohringer D, Seitz B, Engelmann K, et al. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. Eye (Lond). 2009;23(11):2063–70.

    Article  CAS  Google Scholar 

  85. Birnbaum F, Bohringer D, Sokolovska Y, Sundmacher R, Reinhard T. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation. 2005;79(8):964–8.

    Article  CAS  PubMed  Google Scholar 

  86. Birnbaum F, Reis A, Bohringer D, Sokolowska Y, Mayer K, Voiculescu A, et al. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation. 2006;81(5):767–72.

    Article  CAS  PubMed  Google Scholar 

  87. Mitry D, Bhogal M, Patel AK, Lee BS, Chai SM, Price MO, et al. Descemet stripping automated endothelial keratoplasty after failed penetrating keratoplasty: survival, rejection risk, and visual outcome. JAMA Ophthalmol. 2014;132(6):742–9.

    Article  PubMed  Google Scholar 

  88. Price Jr FW, Price MO, Arundhati A. Descemet stripping automated endothelial keratoplasty under failed penetrating keratoplasty: how to avoid complications. Am J Ophthalmol. 2011;151(2):187–8.e2.

    Article  PubMed  Google Scholar 

  89. Heitor de Paula F, Kamyar R, Shtein RM, Sugar A, Mian SI. Endothelial keratoplasty without Descemet stripping after failed penetrating keratoplasty. Cornea. 2012;31(6):645–8.

    Article  PubMed  Google Scholar 

  90. Nottage JM, Nirankari VS. Endothelial keratoplasty without Descemet’s stripping in eyes with previous penetrating corneal transplants. Br J Ophthalmol. 2012;96(1):24–7.

    Article  PubMed  Google Scholar 

  91. Anshu A, Price MO, Price Jr FW. Descemet’s stripping endothelial keratoplasty under failed penetrating keratoplasty: visual rehabilitation and graft survival rate. Ophthalmology. 2011;118(11):2155–60.

    Article  PubMed  Google Scholar 

  92. Bersudsky V, Blum-Hareuveni T, Rehany U, Rumelt S. The profile of repeated corneal transplantation. Ophthalmology. 2001;108(3):461–9.

    Article  CAS  PubMed  Google Scholar 

  93. Chaurasia S, Murthy S, Ramappa M, Mohamed A, Garg P. Outcomes of Descemet’s stripping endothelial keratoplasty in eyes with failed therapeutic penetrating keratoplasty. Acta Ophthalmol. 2014;92(2):167–70.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cornea and External Diseases Service, Moorfields Eye Hospital, London, UK

    Sing-Pey Chow MBBS (Honours), BMedSc FRANZCO & D. Frank P. Larkin MD, FRCPI, FRCS, FRCOphth

Authors
  1. Sing-Pey Chow MBBS (Honours), BMedSc FRANZCO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Frank P. Larkin MD, FRCPI, FRCS, FRCOphth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Frank P. Larkin MD, FRCPI, FRCS, FRCOphth .

Editor information

Editors and Affiliations

  1. Aarhus, Denmark

    Jesper Hjortdal

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chow, SP., Larkin, D.F.P. (2016). Post-operative Management. In: Hjortdal, J. (eds) Corneal Transplantation. Springer, Cham. https://doi.org/10.1007/978-3-319-24052-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-24052-7_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-24050-3

  • Online ISBN: 978-3-319-24052-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation